Home・Aktien・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

117.35 3.11

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

111.89

Max

117.97

Schlüsselkennzahlen
By Trading Economics
Einkommen	8M -61M
Verkäufe	31M 65M
EPS	-0.62
Gewinnspanne	-94.171
Angestellte	273
EBITDA	6M -61M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+14.78% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	777M 9B
Vorheriger Eröffnungskurs	114.24
Vorheriger Schlusskurs	117.35

Kymera Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Aug. 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12. Aug. 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6. Aug. 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5. Aug. 2026, 20:02 UTC

Social Media

News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4. Aug. 2026, 20:04 UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3. Aug. 2026, 19:46 UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31. Juli 2026, 20:06 UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30. Juli 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29. Juli 2026, 19:32 UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28. Juli 2026, 17:42 UTC

News

Social Media

Shares lower despite Guggenheim's price target increase to $135.

27. Juli 2026, 21:03 UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24. Juli 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21. Juli 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20. Juli 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Peer-Vergleich

Kursveränderung

Kymera Therapeutics Inc Prognose

Kursziel

By TipRanks

14.78% Vorteil

12-Monats-Prognose

Durchschnitt 131.33 USD 14.78%

Hoch 155 USD

Tief 112 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kymera Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Kymera Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.